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Summary The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25
chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose
of 200 mg m-2, as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and
antihistamines. This regimen was well tolerated, with <4% of cycles resulting in severe toxicity. No major
objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and
the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial
had no major activity in the treatment of malignant pleural mesothelioma.
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Malignant mesothelioma is almost invariably a lethal tumour
of the pleura or the peritoneum (ratio 2.5: 1); it is linked to
asbestos exposure and its incidence is steadily increasing (De
Klerk and Armstrong, 1992). Diagnosis requires large biopsy
samples and exclusion of metastatic tumours (Henderson et
al., 1992). Computed tomography (CT) is essential for
staging the extent of disease. In most studies, Butchart's
modified staging system is used, based on surgical and
pathological findings; however, recently a TNM classification
has been approved and a conversion table from Butchart's to
the UICC staging system proposed (Langlois and Henderson,
1992; UICC, 1992; Boutin et al., 1993).
Survival ofuntreated patients is poor with a median of less
than 12 months, but with sporadic long-term survivors.
Prognosis is influenced by histological subtype, performance
score and disease extent at diagnosis (Boutin et al., 1993;
Pisani, 1988; Calavrezos et al., 1988; van Meerbeeck, 1994).
Surgery and radiotherapy have little impact on survival in
malignant pleural mesothelioma (Rush et al., 1991; Ball and
Cruickshank, 1990). Numerous chemotherapeutic agents have
been tested but results have generally been disappointing.
Literature reviews indicate some activity for anthracyclines
alone or in combination chemotherapy. Doxorubicin is
considered the single agent with the highest activity, ranging
from 14% to 40%, resulting in a median survival of 14 months
(Kraruf-Hansen and Hansen, 1991; Musk et al., 1992).
The Lung Cancer Cooperative Group (LCCG) of the
EORTC has conducted sequential phase II studies in
malignant pleural mesothelioma with mitoxantrone, epirubi-
cin and etoposide (van Breukelen et al., 1991; Mattson et al.,
1992; PE Postmus, unpublished results). None of these drugs
obtained more than a 15% response rate.
Paclitaxel is a new drug with anti-tumour activity in
several tumour types, such as ovarian cancer, breast cancer
and non-small-cell lung cancer (Rowinsky and Donehower,
1995). The mechanisms of action and resistance, toxicity and
clinical pharmacology have been extensively reviewed
(Rowinsky et al., 1993). Here we report the results of a
multicentre phase II study of the EORTC-LCCG with
paclitaxel in the treatment of chemotherapy-naive patients
with malignant pleural mesothelioma.
Patients and methods
Patients with histologically confirmed malignant mesothelio-
ma of the pleural cavity who had received no prior
chemotherapy were accrued into this study. Pathology was
reviewed centrally. Tumour extension had to be measurable
and classified according to the UICC-TNM atlas (UICC,
1992). Pleural effusion alone was not accepted as evaluable
disease. Previous intracavitary treatment was allowed,
provided no cytotoxic drugs were applied. Patients had to
be older than 18 years and younger than 75 years, with a life
expectancy of more than 3 months; WHO performance status
of 0 to 2, and adequate haematological (granulocyte
count>2 x 109 1-', platelet count> I00 x 109 1 '), hepatic
(bilirubin level< 1.5 times normal), and renal (creatinine
clearance>60 ml min-' or creatinine, 1.5 times normal)
functions were required. At least 4 weeks were to have
elapsed since any prior surgery or radiation therapy. Patients
with symptoms or signs of metastases in the central nervous
system and those with a recent history of cardiac disease or
peripheral polyneuropathy were excluded. Written informed
consent from each patient had to be obtained before patient
entry.
All patients were premedicated with oral dexamethasone
20 mg 12 and 6 h before paclitaxel and with diphenhydra-
mine 50 mg and ranitidine 50 mg (or cimetidine 300 mg)
intravenously 30 min before each paclitaxel infusion. A dose
of 200 mg m-2 paclitaxel (Taxolg, Bristol-Myers Squibb,
Brussels, Belgium) was diluted in 1000 ml of 5% dextrose in
water (or normal saline) and administered over 3 h in non-
polyvinylchloride containers with micropore filters. Blood
counts were checked weekly after administration, and ECG
and liver/renal function controlled before each cycle.
Treatment cycles were repeated every 3 weeks, provided
toxic effects were not prohibitive and there was no clinical
evidence of tumour progression. No dose escalation of
paclitaxel was permitted. Doses were to be reduced to
175 mg m-2 in the event of >7 days neutropenia grade 3
or more, febrile neutropenia or thrombocytopenia > grade 3.
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Paclitaxel was to be discontinued for more than grade 2
neurological toxicity, significant hypersensitivity reactions
and/or treatment delay of > 3 weeks. Administration
continued unless tumour progression, death, patient refusal
or unacceptable toxicity developed, up to a maximum of ten
cycles.
Tumour response was assessed every three cycles and at
the end of treatment, according to WHO criteria (EORTC,
1994). The use of CT scans was mandatory for evaluation of
intrathoracic target lesions. Toxicity was scored according to
the common toxicity criteria of the NCI completed by the
NCIC (EORTC, 1994). This study was planned according to
the two-stage Gehan design aiming at rejecting a drug with a
response rate below 20%, and evaluating the response rate
with a standard error inferior to 10% (Simon, 1989). The
Kaplan-Meier method was used to estimate overall survival
and duration of stabilisation (Kaplan and Meier, 1958).
Results
Between April and October 1993, 25 patients were registered
into the study from eight institutes in Europe. Of these, one
refused to start treatment and no information was received
and one was ineligible because of lack of measurable disease.
The characteristics of 24 registered patients (excluding the
patient never treated) and their tumours are listed in Table I.
The disease was confined to the ipsilateral pleural cavity in
half of the patients. The response and toxicity analysis is
further restricted to the 23 eligible patients.
A total of 128 cycles of paclitaxel were administered. The
median number of cycles per patient was four (range 2-10),
with ten patients receiving at least six cycles. One patient
received only two cycles because of early death owing to
malignant disease. No dose reductions occurred; in five
patients one cycle had to be delayed, but this was not drug
related. Paclitaxel at this dose and schedule resulted in only
moderate toxicity. Table II summarises the toxicities that
occurred across the cycles. Neutropenia grade 3 or more was
the most frequent severe toxicity, appearing in 4% of cycles.
No patients had to be hospitalised because of febrile
neutropenia. Median white blood cell (WBC) nadir count
for all cycles was 4.2 x 109 1-'. Overall, 17 patients (74%)
developed peripheral neuropathy: the grade of neurotoxicity
increased with increasing number of cycles. Paresthesias
occurring after the fourth cycle were always grade >2 and
the cause for treatment discontinuation in one patient. All
severe neurotoxicities lasted for at least 5 months after
treatment discontinuation, or until death. Two-thirds of the
patients developed myalgia and/or arthralgia. This was
moderate in seven and severe in two patients. Unlike
neurological toxicity, this side-effect occurred from the first
course and was not cumulative. Alopecia, anorexia and
nausea were common but not severe. The only episode of
vomiting grade 4 was due to gastric ulceration and
oesophagitis. Seven patients developed a hypersensitivity
reaction, which was never severe. No cardiac toxicity was
observed.
All eligible patients were assessable for response. One
patient died due to malignant disease before response could
be evaluated. There were no major objective responses
(response rate 0%; 95% confidence interval 0%-15%).
Because of the rapid accrual into the study, it proved
infeasible to apply the two-step design as planned, and more
patients were entered than actually necessary to exclude a
20% response rate. Ten patients (44%) remained stable
during chemotherapy, while the remaining 12 (52%) showed
disease progression. The median duration of stabilisation was
30 weeks (range 18 -63 weeks). The median survival time was
9 months, and the 12 and 18 month survival rates were 30%
and 10% respectively (not shown).
Discussion
Most published series of malignant pleural mesothelioma
report a median survival time of less than 1 year. The
percentage of long-term survivors is <5%, and it is doubtful
whether any treatment alters the natural history of the
disease. Disease extent, performance status and histological
subtype appear to be the most important prognostic factors
in this disease (van Meerbeeck, 1994). For the majority of
patients systemic therapy can be considered at some time. In
a review of published series, only 11% of single-agent
chemotherapy studies and 9% of combination chemotherapy
studies were stated to give sufficiently conclusive data
regarding the observed activity (Kraruf-Hansen and Han-
sen, 1991). The majority of the pooled results, however, were
inconclusive, as most studies enrolled only a few patients and
the evaluation procedures were not accurate. Because of the
inefficacy of currently available drugs, most authors feel that
clinical studies in malignant mesothelioma should focus on
phase II trials with new drugs (Vogelsang, 1992; Kraruf-
Hansen, 1994).
One of the greatest problems in the interpretation of the
efficacy of a treatment in this disease is the adequate evaluation
of response. In many of the older studies, this was done on
conventional chest films. Only sequential use of CT scans or
magnetic resonance imaging (MRI) may provide useful
information.
In this study, no therapeutic activity of paclitaxel against
mesothelioma could be observed at a dosage and schedule
that are commonly employed in untreated patients. The
Table I Patient and tumour characteristics in 24 registered and
treated patients
Characteristic No. ofpatients Percentage
Sex
Female
Male
Median age (range), years
Performance status (WHO)
0
1
2
TNM stage
I-II
III -IV
Histological subtype
Epithelial
Mixed
Sarcomatous
Not classifiable
4
20
63 (36-73)
10
13
1
12
12
14
7
2
1
17
83
42
54
4
50
50
59
29
8
4
Table II Toxicities (according to CTC) encountered in 23 eligible
patientsa
Grade
Toxicity 0 1 2 3 4
Neutropenia 11 5 2 2 3
Febrile neutropenia 23 0 0 0 0
Anaemia 14 4 5 0 0
Thrombocytopenia 23 0 0 0 0
Nausea/vomiting 14 5 2 1 1
Diarrhoea 21 2 0 0 0
Mucositis/stomatitis 19 2 1 1 0
Alopecia 2 3 18 - -
HSRb 16 4 3 0 0
Myalgia/arthralgia 7 7 7 2 0
Neurological toxicity 6 9 5 3 0
aThe highest CTC grade for each patient is reported. bHSR,
hypersensitivity reaction.P bkwfo _ _ 90 mo"
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median survival time of 9 months is similar to other phase H
studies in this tumour. In a similar study, preliminary results
reported two partial regressions in 15 malignant mesotheio-
ma patients treated with paclitaxel at a dose of 250 mg m-2
as a 24 h infusion (Vogelsang et al., 1994). The question
arises whether this modest activity is due to the higher dose,
to the 24 h infusion or simply to differences in patients'
characteristics. In refractory ovarian cancer it was observed
that 24 h infusion produced more myelosuppression but did
not yield a higher response. The maximum tolerated dose
(MTD) ofpacitaxel recommended for phase H studies, when
administered as a 3 h infusion, is 210 mg m-2, myelosuppres-
sion being dose limiting (Schiller et al., 1994). The MTD of
paclitaxel administration with CSF support is 250 mg m-2,
neurotoxicity being dose limiting (Schiller et al., 1994). The
toxicity findings of the present study are similar to other
studies employing 3 h infusions ofpacitaxel. Interestingly, in
this study no severe hypersensitivity reaction or cardiac
disturbances occurred.
Cytoplasmic immunoreactivity for P-170 glycoprotein has
been described in the majority of mesothelioma specimens in
one study (Ramael et al., 1992). P-glycoprotein (P-gp)
functions as a drug efflux pump and is associated with the
multidrug-resistance phenotype. Whether this mechanism of
drug resistance contributes to resistance to paclitaxel in
malignant mesothelioma remains speculative. Paclitaxel is,
however, a substrate of P-glycoprotein and overexpression of
P-gp has been shown to be responsible for resistance to
paclitaxel in mammalian cell lines (Gupta, 1993).
In conclusion, pacitaxel was well tolerated at this dose
and schedule in patients with chemotherapy-untreated
malignant pleural mesothelioma. The absence of major
objective responses does not warrant further testing of
pacitaxel in this disease.
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